Can-Fite Biopharma reported Phase 2a results for namodenoson in advanced pancreatic ductal adenocarcinoma, pushing investor focus toward the drug’s safety profile and durability of overall survival outcomes. In an open-label study of 20 patients whose disease progressed after standard therapies, the company said the trial met its primary safety endpoint. Can-Fite also reported median overall survival extending past five months and described the medication as well tolerated, with a safety profile consistent with prior studies. The receptor target is A3 adenosine, and the company highlighted durable OS signals across lines of treatment. The update adds a catalyst for the company ahead of future development decisions, especially in a field where PDAC outcomes remain difficult to improve with small-molecule approaches.